Search - tctmd.com

Displaying 581 - 600 of 1006

Sort: Relevancy | Date

Presentation TCT 2016

Treatment of Renal Artery Fibromuscalar Dysplasia: Indications, Techniques, and Outcomes

Presenter: Gary M. Ansel, Michael R. Jaff, Mehdi H. Shishehbor

October 30, 2016

Presentation TCT 2016

Surgical Outcomes in Primary MR: Results From Expert Surgeons vs Real Life Surgeons

Presenter: Michael J. Mack, Francesco Maisano, Patrick M. McCarthy

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Michael J. Mack

October 30, 2016

Presentation TCT 2016

Debate: ICD or Pacemaker for High Grade AV Block After Alcohol Septal Ablation: Pro Pacing

Presenter: Bernard J. Gersh, Harry Rakowski, Michael A. Fifer

October 30, 2016

Presentation TCT 2016

Hypertension Treatment Targets Beyond the Kidneys

Presenter: Felix Mahfoud, Michael A. Weber, Atul Pathak

October 30, 2016

Presentation TCT 2016

Do the Benefits of Bivalirudin Translate to Radial Intervention? Evidence From Randomized Trials

Presenter: A. Michael Lincoff, Franz-Josef Neumann, John A. Bittl

October 30, 2016

Presentation TCT 2016

The Renal Nerves and Their Role in Hypertension: An Updated Synthesis (Anatomy and Pathophysiology)

Presenter: Felix Mahfoud, Michael A. Weber, Michael Joner

October 30, 2016

Presentation TCT 2016

Should Bivalirudin Only Be Used With a Prolonged Post-PCI Infusion?

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Gregg W. Stone

October 30, 2016

Presentation TCT 2016

Start With a Three-way Debate: Bivalirudin Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Harvey D. White

October 30, 2016

Presentation TCT 2016

Is There a Role for PCI of Renal Artery Stenosis in Hypertension Management?

Presenter: Felix Mahfoud, Michael A. Weber, Ehtisham Mahmud

October 30, 2016

Presentation TCT 2016

Start With a Three-way Debate: Heparin Plus Routine Use of GP IIb/IIIa Inhibitors Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Jorge F. Saucedo

October 30, 2016

Presentation TCT 2016

Atrial Fibrillation: Scope of the Problem

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Michael D. Ezekowitz

October 30, 2016

Presentation TCT 2016

Start With a Three-way Debate: Heparin Monotherapy Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann

October 30, 2016

Presentation TCT 2016

Implications of Recent Hypertension Studies for Optimal BP Targets and Clinical Practice (SPRINT, PATHWAYS, Others)

Presenter: Felix Mahfoud, Michael A. Weber

October 30, 2016

Presentation TCT 2016

Recognition and Treatment of Right Ventricular Cardiogenic Shock

Presenter: Stefan K. James, Holger Thiele, Michael J. Lim

October 30, 2016

$Treatment of Refractory Cardiogenic Shock With ECMO$

Presentation TCT 2016

Treatment of Refractory Cardiogenic Shock With ECMO

Presenter: Stefan K. James, Holger Thiele, Michael Mooney

October 30, 2016

News Conference News TCT 2016

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Michael O'Riordan

October 30, 2016

Presentation TCT 2016

Personalized Medicine Where Are We in 2016?

Presenter: Robert A. Harrington, A. Michael Lincoff, Clyde W. Yancy

October 30, 2016

Presentation TCT 2016

Anti-inflammatory Therapies for Atherosclerosis

Presenter: Robert A. Harrington, A. Michael Lincoff, Jean-Claude Tardif

October 30, 2016

Presentation TCT 2016

Heart Failure Advances (Ivabradine, ARNI, and More)

Presenter: Robert A. Harrington, A. Michael Lincoff, Clyde W. Yancy

October 30, 2016

Advertisement

Treatment of Renal Artery Fibromuscalar Dysplasia: Indications, Techniques, and Outcomes

Surgical Outcomes in Primary MR: Results From Expert Surgeons vs Real Life Surgeons

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Debate: ICD or Pacemaker for High Grade AV Block After Alcohol Septal Ablation: Pro Pacing

Hypertension Treatment Targets Beyond the Kidneys

Do the Benefits of Bivalirudin Translate to Radial Intervention? Evidence From Randomized Trials

The Renal Nerves and Their Role in Hypertension: An Updated Synthesis (Anatomy and Pathophysiology)

Should Bivalirudin Only Be Used With a Prolonged Post-PCI Infusion?

Start With a Three-way Debate: Bivalirudin Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Is There a Role for PCI of Renal Artery Stenosis in Hypertension Management?

Start With a Three-way Debate: Heparin Plus Routine Use of GP IIb/IIIa Inhibitors Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Atrial Fibrillation: Scope of the Problem

Start With a Three-way Debate: Heparin Monotherapy Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Implications of Recent Hypertension Studies for Optimal BP Targets and Clinical Practice (SPRINT, PATHWAYS, Others)

Recognition and Treatment of Right Ventricular Cardiogenic Shock

Treatment of Refractory Cardiogenic Shock With ECMO

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Personalized Medicine Where Are We in 2016?

Anti-inflammatory Therapies for Atherosclerosis

Heart Failure Advances (Ivabradine, ARNI, and More)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content